Prednisone

證據等級: L5

預測適應症: 10 個

Prednisone: From Inflammatory & Autoimmune Conditions to Alopecia Areata

One-Sentence Summary

Prednisone is a broad-spectrum oral corticosteroid, traditionally used to control inflammatory and autoimmune conditions across multiple organ systems. The TxGNN model predicts it may be effective for Alopecia Areata, with 32 clinical trials and 20 publications currently returned as supporting context, though only a small subset directly test prednisone in this indication.

Quick Overview

Item	Content
Original Indication	Anti-inflammatory / immunosuppressive therapy (corticosteroid class) — no specific SAHPRA-approved indication text on file
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L2
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, prednisone is part of the systemic glucocorticoid class; its anti-inflammatory and immunosuppressive efficacy has been proven across numerous autoimmune and inflammatory conditions, and mechanistically this action may extend to alopecia areata.

Alopecia areata (AA) is a T-cell-mediated autoimmune attack on the hair follicle. Prednisone suppresses lymphocyte activation and inflammatory mediator release, giving it a direct mechanistic link to AA pathophysiology. It is already used off-label in clinical practice as a systemic treatment option for severe or rapidly progressive AA, particularly in combination with methotrexate.

The strongest supporting evidence in this pack is a completed Phase 3 RCT (NCT02037191) and a corroborating 2023 JAMA Dermatology RCT (PMID 36884234), both testing low-dose prednisone combined with methotrexate in severe AA (totalis/universalis). Much of the remaining clinical-trial evidence returned by the model relates to other drugs in immune-mediated diseases (e.g. SLE) sharing overlapping immune pathways rather than prednisone itself — useful as mechanistic corroboration, but not direct efficacy evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02037191	Phase 3	Completed	90	RCT of methotrexate alone vs. methotrexate + low-dose prednisone vs. placebo in severe AA (totalis/universalis) — the most directly relevant trial for this candidate
NCT04925934	Phase 2	Completed	214	VIB7734 (anti-ILT7) trial in immune-mediated disease; supports the relevance of immune-pathway modulation to AA, but does not test prednisone directly
NCT04058028	Phase 2b	Completed	244	Rozibafusp Alfa dose-ranging study in autoimmune disease with inadequate response to standard of care; mechanistic pathway relevance only
NCT03616964	Phase 3	Completed	778	Baricitinib RCT; confirms that the immune pathway implicated in AA is druggable, but not prednisone-specific evidence
NCT07332481	Phase 3	Not yet recruiting	202	Enpatoran (ELOWEN-1) in cutaneous immune-mediated disease — indicates active R&D in the disease space; study drug is not prednisone
NCT07355218	Phase 3	Not yet recruiting	202	Enpatoran (ELOWEN-2), twin trial to the above

Several additional trials returned by the model (e.g. cabazitaxel/prednisone in prostate cancer, R-CVP lymphoma regimens) were excluded from this table as they reflect prednisone’s use as a chemotherapy adjunct in unrelated oncology indications and are not relevant to AA.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36884234	2023	RCT	JAMA Dermatology	2-step double-blind RCT: methotrexate alone vs. methotrexate + low-dose prednisone in AA totalis/universalis
4571041	1973	Cohort	Archives of Dermatology	Immunologic studies of AA and treatment outcomes with prednisone
791152	1976	Cohort	Archives of Dermatology	Follow-up report on prednisone therapy for AA; initial response seen but long-term benefit and side-effect burden (acne, obesity, hypertension) noted
911178	1977	Cohort	Archives of Dermatology	Further cohort data on prednisone therapy for AA
26735937	2016	Cohort	Dermatology (Basel)	Efficacy and safety of methotrexate combined with low-to-moderate dose corticosteroids in severe AA
20804894	2010	Cohort	Annales de Dermatologie et de Vénéréologie	Evaluated efficacy/safety of once-monthly oral pulsed prednisone in AA management
8996277	1997	Cohort	Journal of the American Academy of Dermatology	Systemic cyclosporine plus low-dose prednisone in chronic severe AA, with immunopathologic evaluation
9732014	1998	Cohort	International Journal of Dermatology	Severe AA treated with systemic corticosteroids; demonstrated as an effective treatment option
38650498	2024	Cohort	Italian Journal of Dermatology and Venereology	Real-world evidence on hospitalized AA patients in Italy, including treatment patterns
1444509	1992	Review	Archives of Dermatology	Review of AA therapies covering efficacy, safety and mechanism across treatment options including corticosteroids

South Africa Market Information

Prednisone is currently listed as not marketed in this evidence pack, with 0 SAHPRA registrations captured. No product-level registration data (registration number, product name, dosage form) was available to tabulate.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 3 RCT (NCT02037191) together with a 2023 RCT (PMID 36884234) directly test low-dose prednisone (combined with methotrexate) in severe AA, meeting the L2 evidence bar. However, the drug currently has no SAHPRA registration in South Africa, and key safety/prescribing data (warnings, contraindications, MOA) are marked as data gaps in this pack, so this cannot yet proceed to standard clinical use without further verification.

To proceed, the following is needed:

SAHPRA-approved Professional Information (warnings, contraindications, DDI) — currently a blocking data gap
Formal mechanism-of-action / DrugBank classification data
Confirmation of a market-access pathway in South Africa given the current “not marketed” / 0-registration status (e.g. Section 21 access or new registration)
Dosing-specific evidence review, since most supporting studies use low-dose, pulsed, or methotrexate-combination prednisone regimens rather than monotherapy at standard doses
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.